Type: Oral
Session: 909. Education, Communication, and Workforce: Bridging the Gap: Enhancing Communication and Education for Hematologists and our Patients
Hematology Disease Topics & Pathways:
Research, Health outcomes research, Workforce, Young adult , Study Population, Human
Objective: To describe how the engagement between AYA with SCD and CHWs utilizing the IMPaCT model (Kangovi et al 14) facilitates self-management and advocacy skills for successful transition to adult care.
Methods: The COMETS study is a randomized clinical trial comparing the effectiveness of two self-management support interventions (CHWs and mobile health) versus usual care to improve health-related quality of life for transitioning AYA with SCD. Participants (n=405) were at least 17 years old, receiving care at one of five children’s hospitals in four US states (NY, OH, CT, PA), spoke English as a primary language, and were appropriate to transition to an adult hematologist in the next 12 months. Enrolled participants were randomized to receive a CHW, access to an mHealth app, or usual care for a 6-month period. This analysis focuses on the 120 participants randomized to the CHW arm, which used the IMPaCT model. The Individualized Management for Patient-Centered Targets (IMPaCT) model provides a college-accredited CHW training curriculum in which CHWs tailor patient support to their individual health goals (Kangovi et al 14). AYAs randomized to this arm received weekly check-ins from CHWs and support in setting and achieving goals related to health self-management, transition readiness, planning for school/work responsibilities, SCD knowledge, and self-advocacy and health system navigation.
Results: The median participant age was 18.66 years (range: 17.01-28.62), with 52% (n=62) identifying as female and 92% as Black or African American (n=110). Most (68%; n=83) had government sponsored insurance, and 54% (n=65) had severe SCD characterized by history of overt stroke, acute chest syndrome, or 3+ hospitalizations in past 3 years (Beverung et al 2015).
CHWs successfully established contact with 95% (n=111) of participants within a median of 5 days (range:0-132 days) of assignment to a participant. Participants set an average of 2.5 goals (total= 297) categorized as: Improving Skills to Manage Health (e.g., tracking health issues) (32%; n=96); Increasing Knowledge of Planning for School and Work (e.g., workplace skills and expectations) (31%; 94); Increasing knowledge of SCD and Healthcare (e.g., healthy behaviors) (21%; 63); and Improving Skills for Navigating Health Systems and Self-Advocacy (e.g. getting appointments) (15%; 44). Of these, 70% of goals (n=208) were resolved by graduation from the program and 13% (n=16) were abandoned after 1 month.
CHWs made 3021 contacts over the 6-month period (average 25 per participant) primarily via phone (54%; n=1643) and text message (38%; n= 1160). Other modalities included email (2.9%; n=88), in person at a clinic visit (1.5%; n=46), via video conferencing (0.8%; n=23), and in person in a community setting (0.6%; n=17). Of these, 63% (n=1900) contacts were meaningful interactions, defined by the study team as an interaction where CHWs and participants connected and discussed goal progress, averaging 21 minutes (median: 10 minutes; range 0-240 minutes). Participants gave their interaction with CHWs an average rating of 9.6 out of 10.
Conclusion(s): AYA with SCD demonstrated high levels of engagement with CHWs through consistent, weekly contact – predominantly via phone – and goal-oriented discussions. This study supports the effectiveness of tailored interventions, like CHW programs, for marginalized populations such as AYA with SCD. Future work should assess the long-term impact of the CHW intervention on patient outcomes, including ED visits, hospitalizations, and mortality among AYA with SCD.
Disclosures: Jan: Merck: Current holder of stock options in a privately-held company; Vertex: Current equity holder in publicly-traded company. Niss: Pfizer: Consultancy. Andemariam: Novartis: Research Funding; Health Resources and Services Administration: Research Funding; Vertex: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisk: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Hemanext: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Global Blood Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Fulcrum Therapeutics: Other: Data Safety Monitoring Board / Adjudication Committee; Editas: Other: Data Safety Monitoring Board / Adjudication Committee; Connecticut Department of Public Health: Research Funding; bluebird bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; American Society of Hematology: Research Funding; Afimmune: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Accordant: Consultancy, Membership on an entity's Board of Directors or advisory committees. Smith-Whitley: Pfizer: Current Employment.